Definium Therapeutics vs Legend Biotech

Definium Therapeutics (DFTX), health care, and Legend Biotech (LEGN), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Definium Therapeutics is worth $4B on the stock market and Legend Biotech $3.1B: Definium Therapeutics is valued at 29% more. Over the past year Definium Therapeutics's share price has moved +164% and Legend Biotech's -45.6%.

Key facts

Definium Therapeutics market value
$4B
Legend Biotech market value
$3.1B
Legend Biotech revenue
$1BFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Definium Therapeutics vs Legend Biotech: every measure side by side
Measure Definium Therapeutics Legend Biotech
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$4Bhigher$3.1Blower
Revenue—$1B
Earnings-$183.8Mhigher-$296.8Mlower
Employees105lower3,300higher
Total assets$440.1Mlower$1.7Bhigher
Valuation
P/E——
P/S—3.0
P/B4.2higher2.5lower
Dividend yield0.00%0.00%
Profitability
Operating margin—-13.3%
Balance sheet
Net assets$332.3Mlower$1Bhigher
Total liabilities$107.8Mlower$731.6Mhigher
Total debt$40.6Mlower$319.1Mhigher
Cash on hand$257.8Mlower$901.9Mhigher
Price change
Today-2.59%lower+0.75%higher
1 year+164%higher-45.6%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Definium Therapeutics only (2)

Legend Biotech only (1)

Percentages are each holding's share of that investor's reported portfolio. Who owns DFTX · Who owns LEGN

Further comparisons

Learn

Questions and answers

Which is bigger, Definium Therapeutics or Legend Biotech?

By market value, Definium Therapeutics is the larger: $4B against $3.1B for Legend Biotech.

Which has the higher dividend yield?

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which has more debt?

Legend Biotech: $319.1M, against $40.6M for Definium Therapeutics. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Definium Therapeutics and Legend Biotech?

None of the tracked superinvestors holds both in their latest 13F filing. 2 hold Definium Therapeutics and 1 holds Legend Biotech.

Cite this page

Funkfolio, “Definium Therapeutics vs Legend Biotech”, data as of 18 November 2026. https://funkfolio.com/compare/dftx-vs-legn

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.